Last reviewed · How we verify

NCT04253340: TEOBASO

Study of a Bone Assessment Technique, Bone Mineral Analyser, Concerning the Prediction of Improvement in Bone Status After an Infusion of Zoledronic Acid in Osteoporotic Women

Withdrawn NA Last updated 10 February 2026
What this trial tests

NA trial testing Bone mineral analyser in Osteoporosis. Withdrawn.

Timeline
1 March 2020
Primary endpoint
1 March 2023
1 March 2023

Quick facts

Lead sponsorUniversity Hospital, Rouen
PhaseNA
StatusWithdrawn
Study typeINTERVENTIONAL
Allocationna
Designsingle group
Maskingnone
Primary purposeother
Start date1 March 2020
Primary completion1 March 2023
Estimated completion1 March 2023

Drugs / interventions tested

Conditions studied

Sponsor

University Hospital, Rouen

Who can join

Adults 18 to 85, female only, with Osteoporosis. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

* Collection of epidemiological data * Biological assessment as part of routine care. * Measurement of the Hurst coefficient at D0 * Measurement of bone density and TBS on D0 * Zoledronic acid infusion the month following inclusion * phone call at 1 month (observance of zoledronic acid) * Measurement of bone density, calculation of the Hurst coefficient at M12

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other recruiting trials for Osteoporosis

Currently open trials in the same condition.

Other University Hospital, Rouen trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04253340.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing